Hormone therapy and its risk after gynecological malignancy operation / 中国实用妇科与产科杂志
Chinese Journal of Practical Gynecology and Obstetrics
;
(12): 651-654, 2019.
Artículo
en Chino
| WPRIM
| ID: wpr-816231
ABSTRACT
With the improvement of therapy,the survival time of patients with gynecological malignant tumor is prolonged,so improving their quality of life has become a new challenge for doctors.These patients may be in perimenopause themselves,or be in artificial menopause due to tumor treatment,and their climacteric symptoms are more obvious than those in natural menopause.Whether hormone therapy could be used to relieve the climacteric symptoms in these patients is still controversial at present.Clinicians should give individualized hormone therapy cautiously on the basis of patients' informed consent.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Estudio de etiología
Idioma:
Chino
Revista:
Chinese Journal of Practical Gynecology and Obstetrics
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS